TW446552B - Osmotic delivery system with membrane plug retention mechanism - Google Patents
Osmotic delivery system with membrane plug retention mechanism Download PDFInfo
- Publication number
- TW446552B TW446552B TW087121719A TW87121719A TW446552B TW 446552 B TW446552 B TW 446552B TW 087121719 A TW087121719 A TW 087121719A TW 87121719 A TW87121719 A TW 87121719A TW 446552 B TW446552 B TW 446552B
- Authority
- TW
- Taiwan
- Prior art keywords
- capsule
- conveying device
- membrane
- open end
- permeable
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 133
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 34
- 230000014759 maintenance of location Effects 0.000 title claims abstract description 7
- 230000007246 mechanism Effects 0.000 title abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 116
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 82
- 230000009286 beneficial effect Effects 0.000 claims abstract description 46
- 239000000463 material Substances 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 230000008901 benefit Effects 0.000 claims description 28
- 238000011049 filling Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 230000002079 cooperative effect Effects 0.000 claims description 11
- 230000035699 permeability Effects 0.000 claims description 10
- 238000005192 partition Methods 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 5
- 239000007943 implant Substances 0.000 abstract description 5
- 239000002357 osmotic agent Substances 0.000 abstract description 3
- 229920002678 cellulose Polymers 0.000 description 21
- 239000001913 cellulose Substances 0.000 description 20
- 229920000642 polymer Polymers 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- -1 polytetrafluoroethylene Polymers 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 8
- 230000000149 penetrating effect Effects 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000005553 drilling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 229920001747 Cellulose diacetate Polymers 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 229910000640 Fe alloy Inorganic materials 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920013730 reactive polymer Polymers 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- OLDGKMRIXAQGLW-MEYGQTPLSA-N (8R,9S,13S,14R)-15,15-diethyl-13-methyl-7,8,9,11,12,14,16,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@]4(C)C(O)CC(CC)(CC)[C@H]4[C@@H]3CCC2=C1 OLDGKMRIXAQGLW-MEYGQTPLSA-N 0.000 description 1
- OKORHWXYDBSYNO-INIZCTEOSA-N (S)-codamine Chemical class C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(O)=C(OC)C=C2CCN1C OKORHWXYDBSYNO-INIZCTEOSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- PEVRKKOYEFPFMN-UHFFFAOYSA-N 1,1,2,3,3,3-hexafluoroprop-1-ene;1,1,2,2-tetrafluoroethene Chemical group FC(F)=C(F)F.FC(F)=C(F)C(F)(F)F PEVRKKOYEFPFMN-UHFFFAOYSA-N 0.000 description 1
- VWXFUOAKGNJSBI-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-(2,6-dichloroanilino)-2-oxoethyl]piperazine-2-carboxamide Chemical compound C1CN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)C(C(=O)N)CN1CC(=O)NC1=C(Cl)C=CC=C1Cl VWXFUOAKGNJSBI-UHFFFAOYSA-N 0.000 description 1
- KEDVUOWPLAHMLZ-UHFFFAOYSA-N 1-cyano-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-2-prop-2-ynylguanidine Chemical compound CC=1NC=NC=1CSCCNC(NC#N)=NCC#C KEDVUOWPLAHMLZ-UHFFFAOYSA-N 0.000 description 1
- OKCHIIATHDZHJP-UHFFFAOYSA-N 1-phenylbutane-1,1-diol Chemical compound CCCC(O)(O)C1=CC=CC=C1 OKCHIIATHDZHJP-UHFFFAOYSA-N 0.000 description 1
- SEVKYLYIYIKRSW-UHFFFAOYSA-N 1-phenylpropan-2-ylazanium;chloride Chemical compound Cl.CC(N)CC1=CC=CC=C1 SEVKYLYIYIKRSW-UHFFFAOYSA-N 0.000 description 1
- WKQCPUMQBMFPLC-ZWFCQKKLSA-N 11beta,21-Dihydroxypregn-4-ene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O WKQCPUMQBMFPLC-ZWFCQKKLSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- HWALZPBPZSMSGA-UHFFFAOYSA-N 2-cyclohexyl-n,n-diethylethanamine Chemical compound CCN(CC)CCC1CCCCC1 HWALZPBPZSMSGA-UHFFFAOYSA-N 0.000 description 1
- UCQVUNUTHKGDJR-UHFFFAOYSA-N 2-ethoxy-2-phenylpropanoic acid Chemical compound CCOC(C)(C(O)=O)C1=CC=CC=C1 UCQVUNUTHKGDJR-UHFFFAOYSA-N 0.000 description 1
- ICPWFHKNYYRBSZ-UHFFFAOYSA-N 2-methoxypropanoic acid Chemical compound COC(C)C(O)=O ICPWFHKNYYRBSZ-UHFFFAOYSA-N 0.000 description 1
- XFLSUQGAZBASBN-UHFFFAOYSA-N 2-methylpyrrolidin-1-amine Chemical compound CC1CCCN1N XFLSUQGAZBASBN-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- SEYXJSRNSAARCP-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine;hydrochloride Chemical compound Cl.C1=CC=C2NCCOC2=C1 SEYXJSRNSAARCP-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- BTVVEKSXUOEVAY-UHFFFAOYSA-N 4,4-diphenylpiperidine Chemical compound C1CNCCC1(C=1C=CC=CC=1)C1=CC=CC=C1 BTVVEKSXUOEVAY-UHFFFAOYSA-N 0.000 description 1
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- RSNWBYSRXLMOJE-UHFFFAOYSA-N Br(=O)(=O)O.[Ar] Chemical compound Br(=O)(=O)O.[Ar] RSNWBYSRXLMOJE-UHFFFAOYSA-N 0.000 description 1
- XKLFKHVHLKWQRL-UHFFFAOYSA-N C(C)(=O)O.CC1=C(NC=C1)C Chemical compound C(C)(=O)O.CC1=C(NC=C1)C XKLFKHVHLKWQRL-UHFFFAOYSA-N 0.000 description 1
- DLGKFGFBUJZANB-UHFFFAOYSA-N C(C)(=O)OC.C1(=CC=C(N)C=C1)C1=CC=C(N)C=C1 Chemical compound C(C)(=O)OC.C1(=CC=C(N)C=C1)C1=CC=C(N)C=C1 DLGKFGFBUJZANB-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 229920001560 Cyanamer® Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101500024559 Homo sapiens Pancreatic hormone Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GIAAMDUXZKKAIW-UHFFFAOYSA-N N.N1N=CC=CC=C1 Chemical compound N.N1N=CC=CC=C1 GIAAMDUXZKKAIW-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- QLDNWJOJCDIMKK-UHFFFAOYSA-N Obtusifoliol Natural products CC12CCC(O)C(C)C1CCC1=C2CCC2(C)C(C(C)CCC(=C)C(C)C)CCC21 QLDNWJOJCDIMKK-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical group FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- SOELXOBIIIBLRJ-UHFFFAOYSA-M choline theophyllinate Chemical compound C[N+](C)(C)CCO.CN1C(=O)N(C)C([O-])=C2N=CN=C21 SOELXOBIIIBLRJ-UHFFFAOYSA-M 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229950007285 etintidine Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- MBGJRCZMULFKGD-UHFFFAOYSA-N fluoro(propan-2-yloxy)phosphinic acid Chemical compound CC(C)OP(O)(F)=O MBGJRCZMULFKGD-UHFFFAOYSA-N 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- SNWQUNCRDLUDEX-UHFFFAOYSA-N inden-1-one Chemical compound C1=CC=C2C(=O)C=CC2=C1 SNWQUNCRDLUDEX-UHFFFAOYSA-N 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940018435 isoproterenol sulfate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229950008080 mioflazine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PECVIWCUAPHWFY-UHFFFAOYSA-N n-ethyl-1h-pyrrol-2-amine Chemical compound CCNC1=CC=CN1 PECVIWCUAPHWFY-UHFFFAOYSA-N 0.000 description 1
- YXMXAXHPRPWBJB-UHFFFAOYSA-N n-phenoxy-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNOC1=CC=CC=C1 YXMXAXHPRPWBJB-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- CBHCDHNUZWWAPP-UHFFFAOYSA-N pecazine Chemical compound C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 CBHCDHNUZWWAPP-UHFFFAOYSA-N 0.000 description 1
- 229950007538 pecazine Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- ZCMHTJJXLONNJS-UHFFFAOYSA-N piperidine;propanedioic acid Chemical compound C1CCNCC1.OC(=O)CC(O)=O ZCMHTJJXLONNJS-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002098 polyfluorene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000005518 polymer electrolyte Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- VMLAEGAAHIIWJX-UHFFFAOYSA-N propan-2-amine hydroiodide Chemical compound [I-].C(C)(C)[NH3+] VMLAEGAAHIIWJX-UHFFFAOYSA-N 0.000 description 1
- 150000003151 propanoic acid esters Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- MPVSPHKBQDMOHE-UHFFFAOYSA-J tetrabromoosmium Chemical compound Br[Os](Br)(Br)Br MPVSPHKBQDMOHE-UHFFFAOYSA-J 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Description
\ 446552 Λ 7 ΒΤ 籴濟部中央裙導局員工消"合作社印^ 五、發明説明(1 發明背景 發明範疇 本發明係關於用於輸送有益劑之渗透性輸送系统,及更 於具有'種滲透性器具(engme)及容許液體通 過進入滲透性器具之—種膜塞之—種參透性輸送系統。 相關技藝之說明 於醫學及獸醫學領域中,有益劑(諸如藥物)之受控制之 輸运已㈣由各種方法而達成3用於有益劑之受控制之延 遲輸送之了種方法包料透性輸送系统之使用。此等系統 可係植入於一人體或動物之身體内、以一種受控制之方式 於一預先選擇之時間或施藥期間内釋出有益劑。通常,滲 透性輸运系統係經由自外部環境吸收液體及釋出對應數量 之有益劑而操作。 一種已知之參透性輸送系統’通常稱爲一種"滲透性泵,, ’通常包括某種類型之具有一種半滲透性部分之一種膠囊 或圍壁,此種半滲透性部分選擇性地通過水進入包含一種 吸引水之滲透劑之膠囊之内部中。於—種已知之滲透性輸 送系統中’释囊之壁對於膠囊之内及之外之物件實質上係 不能透過的。將一種膜塞插入膠囊之—末端及充當半滲透 性部分以谷許水通過進入勝囊之内部3於吸引水之渗透劑 與圍繞膠囊之環境之間之掺透性之差異造成水通過膜塞進 入膠囊中’其轉而致使於膠囊之内之有益劑通過一種輸送 孔口而輸送,吸引水之滲透劑可係輸送至病患之有益劑: 然而’於大多數之案例中使用—種分別之滲透劑,特別地 本紙伕尺度適用中囡固家鏢皁(CiVS ) A4规格(2i〇x297公沒 (請先閲讀背面之注意事項再填寫本頁)
經濟部中央標準局貝工消费合作社印¾ 446552 Λ7 '_______B7__ 五、發明説明(2 ) 利用其之吸收水進入膠囊中之能力。 當使用一種分別之滲透劑時,滲透劑可係經由一種可移 動之分隔膜或活塞而於膠囊之内與有益劑分離。膠囊之結 構係致使當滲透劑吸收水及膨脹時膠嚢不膨脹。當滲透劑 膨脹時’其致使活塞移動及有益劑係通過輸送孔口以相同 於液體(其通常係水)經由滲透而進入滲透劑之速率排出。 參透性輸送系統可係設計爲以一種受控制之固定速率、一 種變動之速率、或以一種悸動之方式輸送一種有益劑。 於已知之滲透性輸送系統中,通常使用一種滲透性片劑 作爲滲透劑及其係置於膠囊之内鄰接活塞。膜塞係置於在 膠囊中之一開口中,通過其將片劑及活塞插入a已知之膜塞 通常係圓柱之構件,其密封膠囊之内部隔離外部環境,僅 容許某些液體分子自使用之環境通過膜塞而滲透進入膠囊 之内部中。液體通過膜塞滲透之速率控制滲透劑膨脹之速 率及驅動有益劑自輸送系統通過輸送孔口。有益劑自麥透 性輸送系統之輸送速率可係經由變動有益劑輸送孔口之尺 寸、滲透性材料、膜塞之尺寸及形狀、或膜塞之滲透係數 而控制。 一膜塞之參透係數係視於塞中使用之特定之材料或材枓 之组合而定。因此,有益劑之輸送速率可係經由自不同之 具有致使於需要之輸送速率輸送有益劑之滲透係數之半參 透性材料形成相同構造之膜塞而控制》與以此種方式獲得 不同之滲透速率相關之一項問題係,對於具有不同之需要 之有益劑輸送速率之每種系統,必須使用一種不同之膜材 -5- 本纸伕尺度適用中國國家標準(CNS ) A4現格(210X 297公兑) (請先閱讀背面之注意事項再填寫本頁)
446552 AT β: 經濟部中央標华局員工消贤合作社印- 五、發明説明(3 ) 料,需要購買多種不同之膜材料及製造多種不同之膜塞= 使用膜塞之多種滲透性輸送系統具有相關於自膠囊排出 膜塞之問題。於已完全地‘輸送有益劑之後’當滲透劑繼續 吸收水進入膠囊中及驅使膜塞離開膠囊時,可發生棑出。 某些之滲透性輸送系統使用膠或黏合劑以避免膠囊次漏及 確保膜塞留在位置中,以避免有害之物質自膠囊之内部漏 出進入環繞之環境中。除了增加一製造步驟及增加成本以 外,對於膜塞施用一種黏合劑可能影響滲透之速率。 於設計以容許有益劑於約1天至2星期之時間期間内之完 全輸送之輸送速率輸送一種有益劑之系統中使用之膜塞對 於膜排出問題係特別敏感的。甴於在植入之數小時之内水 吸入’因此此等快速輸送膜潤脹及變成不穩固及似海缔 的。此等膜之快速潤脹趨於致使膜自膠囊排出。 由於與目前滲透性輸送系統膜塞相關之以上認明之問 題’因此提供以不同之需要輸送速率施用有益劑並且避免 膜塞之排出之滲透性輸送系統係困難的並且昂貴的。 發明摘述 根據本發明’ 一種渗透性植入物具有—種膜塞,其·;聞脹 進入膠囊之側壁中之孔中以固定膜於位置中。 根據本發明之一項態樣’一種滲透性輸送裝置包括具有 一種實質上圓简形側壁、具有一種有益劑輸送孔口之第一 末端、及第二開口端之一種輸送裝置醪囊。一種分隔構件 係安置於輸送裝置膠囊内及於輪送裝置膠囊之内於縱向中 係可移動的,以分配有益劑。將一種參透性器具置於鄰接 _________:6- 本狄張尺度通用中囷國家標孪(CMS > A4規格( --—- (請先閲讀背面之注意事項再填寫本買) .t' 訂 涑 446552 Λ: Β1 蛵濟部中央標準局負工消贤合作社印策 五、發明説明(4 ) 分隔構件之一側。於鄰接輸送裝置膠囊之第二開口端之實 質上圓筒形側壁中形成多個之開口。一種膜塞係安置於輸 送裝置膠囊之第二開口端之内及覆蓋於實質上圓筒形侧壁 中之每個之多個開口。膜塞係經由多個開口而保持於膠囊 中。 根據本發明之另一項態樣,膜塞係由一種材料形成,此 種材料潤脹造成一部分之膜塞延伸進入於側壁中之開口 中’增加於膜塞與輸送裝置膠囊之間之摩擦及防止膜塞自 輸送裝置膠囊排出。 根據本發明之另一項態樣,一讀渗透性輸送裝置包括一 種輸送裝置本體,其包含將通過輸送裝置本體之一種輸送 孔口而輸送之一種有益劑、及用於吸牧外部液體進入輸送 裝置本體以致使有益劑受輸送之一種滲透劑。一種膜塞係 固牢於輸送裝置本體之一開口端中及容許外部液體通過膜 塞進入輸送裝置本體。膜塞係經由於輸送裝置本體中圍繞 輸送裝置本體之開口端形成之多個孔而固牢於輸送裝置本 體之開口端中β膜塞係可膨脹的以延伸進入多個之孔中, 以防止膜塞自輸送裝置本體之排出。 根據本發明之一項另外之態樣,具有一種可控制之有 益劑輸送速率之一種可植入滲透性有益劑輸送裝置包括具 有一種有益劑輸送孔口及一種開口端之一種實質上圓筒形 之本體。於實質上圓筒形之本體之一側壁中於開口端形成 多個之開口。多個之開口係屬於爲了達成一種預定之有益 劑輸送速率所決定之尺寸及數目。於本體之開口端中容納 本纸&尺度14用中關( CNS Μ峨格(2丨ox w公楚) (請先閱讀背面之注意事項再填寫本更) ^. 缘 經1农部中央標萍局員工消費合作社印戈 S46552 Λ7 B7 〜 ________ _ ___ 五、發明説明(5 ) 一種膜塞及其覆蓋多個之開口。 根據本發明之另一種添加之態樣,保持一種膜塞於—種 可植入之滲透性裝置中之一種方垮包括下列之階段:形成 一種實質上圓柱形之膜塞;於一種膠囊之側壁中鄰接膠囊 之一開口端形成孔;將實質上圓柱形之膜塞插入勝囊之開 口端中致使膜塞覆蓋於侧壁中形成之孔;及致使膜塞潤脹 進入於側壁中之孔中以保持膜塞於膠囊中。 本發明經由變動膜保持開口之數目及尺寸而提供改良之 膜保持之利益及達成一種需要之有益劑輸送速率之能力s 圖之簡要說明 本發明將係參考附隨之圖而較詳細地説明,其中相似之 元件帶有相似之參考號碼,及其中: 圖1係根據本發明之一種滲透性藥物輸送裝置之一侧剖面 圖; 圖2係圖1之滲透性藥物輸送裝置之一側面圖; 圖3係具有一種膜塞之一種選擇之具體實施例之一種療透 性藥物輸送裝置之一側剖面圖;及 圖4係比較根據本發明之滲透性藥物輸送裝置之有益劑輸 送速率與具有一種習用之膠囊之一種滲透性藥物輸送裝置 之一線圖5 較佳具體實施例之說明 本發明係關於用於一種有益劑之受控制之輸送之一種笨 透性輸送系統。滲透性輸送藥物輸送裝置1 〇,如於圖1中 圖示’包括一種修長之實質上圓筒形之園壁或膠囊丨2,其 -8 - 本紙乐尺度適用中國囷家樣莩(CNS } A4ii兄格(21〇>< 297公疫) {請先閲讀背面之注意事項再填芎本頁}
*1T 經濟部中央標挛局員工消资合作社印製 446652 、7 B7 五、發明説明(6 ) 具有一個開口端14。膠囊12相對於開口端14之一個末端 具有一個或一個以上輸送開口 16,以輸送包含於滲透性輸 送裝置10之第一室18之内之一種有益劑。修長之膠囊12 係由一種材料形成,此種材料係足夠剛性的以抵抗於輸送 裝置10之第二室20之内包含之一種滲透劑之膨脹而不改變 尺寸或形狀。修長之膠囊12對於在環境中之流體及對於在 滲透性輸送装置1 〇之内包含之成分較佳地係實質上不能滲 透的,致使此等物質之通過膠囊之不能滲透之材料移動進 入或離開裝置係缓慢的,以致於對於滲透性輸送裝置之功 能實質上不具有不利之影響。 於膠囊12之第二室20中之滲透劑係經由一種可移動之分 隔構件或活塞22而與於第一室18中之有益劑分隔。可移動 之分隔構件或活塞2 2係一種實質上圓柱形構件,其係成型 以於一種密封之方式適合於膠囊12之内,其容許活塞沿著 縱向於膠囊之内滑動。活塞2 2較佳地係由一種彈性之材料 形成,其對於在勝囊之内之组合物係不能滲透的及包括環 狀之突起部分24 ’其與膠囊12之内部表面形成一種密封。 如於圖1中圖示’本發明之一種具體實施例之藥物輸送裝 置10包括一種膜塞26 ’其係於將滲透劑置於勝囊之第二室 20内之後’插入醪囊12之開口端14之中。膜塞26容許液 體自使用環境通過進入膠囊1 2中以造成渗透劑潤躁。然 而,形成半滲透性膜塞26之材料對於在膠囊12之内之物質 及對於在使用之環境内之其他成分主要地係不能滲透的。 根據本發明之滲透性輸送系統膜塞2 6之構造決定通過膜 ____-9- 本纸張尺度適用中國國家標準(CNS ) Α4規格(21(^ 297,6¾ )------ (請先閱讀背面之注意事項再填寫本頁)
44Θ552 Λ" 五、發明説明( 塞之液體滲透速率,其轉而控制一種有益劑自滲透性輸送 系统之輸送速率。一種特定之膜塞之液體滲透速率係視膜 材料及膜形狀而定。 圖2圖示根據本發明之一種具體實施例之一種滲透性輸送 系統10之一側面圖,其具有一種膜塞26及於膠囊12中之 多個之孔30,其用於保持膜塞及控制有益劑輸送速率。半 滲透性膜塞2 6係圓柱形形狀,及於膜塞之外部密封表面與 膠囊12之間具有緊密之干抄配合(interference fit)。根據本 發明之選擇之具體實施例,膜塞26亦可包括自膜塞之外部 表面延伸之肋 '或可包括其他之構造諸如螺紋、膠、黏合 劑、脊、唇、或其他裝置,其等密封膜塞至膠囊12之内部 壁以避免洩漏。肋可對應地嚙合於膠囊12之内壁中之成形 之溝槽°於膜塞2 6與膠囊1 2之間之配合較佳地係一種干涉 配合,其避免有意義之鹽洩漏s 經濟部中央標孽局另工消费合作社印^ (請先閱讀背面之注意事項再填rtT本頁) % 於膠囊12之内壁上於開口端14亦可提供一種向内方向之 環狀唇以提供膜之另外之保持。膜塞2 6係計畫爲至少部分 地插入膠囊12之開口端14中’及緊密之干涉配合避免於使 用之環境中之液體及其他物質(除了滲透液體以外)進入滲 透性輸送系統1 0中而同時亦避免物質自輸送系統之内部洩 漏或逸出至使用之環境。 膜塞26包括一種停止表面(st〇p surface) 3 2,當摸塞係完 全地插入時’其自塞徑向地延伸及鄰接膠囊之末端壁3或 者’膜塞26不需要具有停止表面32及塞可係完全地插入一 種滲透性輸送系統之膠囊1 2之開口端1 4之内a同樣地,膜 _ 10 * 本纸乐尺度逋用中國國家榡羋(CNS ) A4規格(21〇x297公楚) 446552 λ' Β1 五、發明説明(8 ) 塞2 6可係部分地插入滲透性輸送系統膠囊i 2之開口端j 4 之中。 ir 由於至少部分之膜塞26係於勝囊12之内,因此僅一部分 之膜塞曝露於在使用之環境中之液體。於圖1及2中圖示之 本發明之具體實施例中,半滲透性膜之—末端表面34係曝 露於在使用之環境中之液體。此外,膜鄰接於膠囊j 2之側 壁中之孔3 0之部分係曝露於環境中之液體。末端表面3 4較 佳地具有平滑或寶曲之角,其對於植入物係比尖銳之邊緣 較可接受的。末端表面34之外徑,垂直於輸送裝置之縱 向中心軸測量’係約相等於滲透性輸送裝置之外徑,以使 於膠囊與本體32之液體表面之間之界面係不含尖銳邊緣、 脊、或尖稜角。 線 鲤濟部中央標羋局β工消费合作社印製 如於圖2中表示,多個之孔3 0係分隔園繞膠囊〗2之開口 端14 ^孔30容許膜塞26潤張進入孔口,於膜塞與内部膠 囊壁之間產生大之摩擦力’其避免膜塞排出。於膠囊12與 膜塞2 6之間之摩擦力係直接地相關於在膠囊壁中之孔3 〇之 數目、位置、及形狀及膨張進入孔中之塞材料之數量。可 決定多個孔30之尺寸及排列彼等以達成需要之摩擦力,然 而,每個之孔應係由膜塞2 6完全覆蓋,致使不能發生渗透 劑洩漏。例如’可提供於兩個與2 〇個之間之變動直徑之 孔。對於大直徑之膠囊1 2,只要維持膠囊之完整性,則孔 30之數目亦可大於20。 於膠囊壁中多個之孔30亦增加曝露之膜塞表面面積,增 加通過膜塞之液體滲透速率=膜塞之增加之曝露面積將比 __ -11 - 本紐又度適财關家標洋(CN'S ) A4規格(210X297公兑.) 446552 Λ" B7 9 五、發明説明( 不具有孔3 0之相同系統縮短啓動用於開始有益劑輸送之期 間。 (請先閲讀背面之注意事項再填寫本頁) 於一種滲透性輸送系統中,通過一半滲透性膜之液體滲 透速率dV/dt係視液體滲透性及膜之形狀而定。對於不具有 孔之一種習用之膠囊,液體滲透速率dV/dt係由下列式決 定: dV/dt = k;r〔+j
其中 Λ T A ---2L. 4 膜塞之曝露末端表面34之直徑及k係將液體滲透速 率及於一種中空膜塞之膜壁之厚度或一種實體膜塞之長度 列入考慮之一常數。 對於根據本發明具有多個之圓形孔3〇之一種滲透性輸送 裝置,液體滲透速率dV/dt係由下列式決定·· dV/dt= 超濟部中央標準局員工消费合作社印裝
其中 Α = Υ +孔之數目 D m係曝露之膜塞末端表面3 4之直徑’ D h係孔3 0之直 徑、及k係將膜塞材料及厚度或長度列入考慮之常數。 於圖1之具體實施例中,液體滲透速率dV/dt亦受到於膠 -12- 本紙伕尺度適用中國國家標準(CNS ) Λ4坭格(210X 297公犮) 446552 經濟部中央標準局κ工消f合作社印焚 Λ: Β· 五、發明説明(10 ) 囊上孔30之縱向位置影響。液體必須通過膜移動之距離愈 短,則液體將滲透膜愈快速=於是,孔3 0對於鄰接第二室 20之膜塞之未端愈接近,則釋出速率愈快速。 如自前述可看出,液體渗透速率及因此,有益劑輸送速 率可係經由改變孔3 0之直徑及/或數目而控制,不需要改 變滲透性輸送裝置10或膜塞26之整體幾何形狀。輸送速率 亦可係經由變動孔之縱向位置而控制。 於圖3中圖示之本發明之一種選擇之具體實施例包括具有 一中空内部及一實質上固定厚度圓筒形側壁40與末端壁42 之一種膜塞2 6 a。於用於在短暫時間期間諸如1至4 2天之内 輸送一種有益劑之快速輸送系統中,中空膜塞2 6 a係特別 有用的。於此種具體實施例中,有益劑輸送速率可係經由 改變孔之直徑及或數目而控制。然而,當改變孔之縱向位 置時,由於滲透液體通過固定厚度側壁4 〇之距離係相同 的,因此輸送速率通常不改變。 於以上敘述之方式,通過膜塞26之液體滲透速率dV/dt可 係經由於膠囊之側壁中形成孔3 〇而簡單地並且有效地控 制。由於可使用相同之膜塞26以形成具有不同之液體滲透 速率之滲透性輸送系統’因此此係有利的。對於具有不同 之需要之有益劑輸送速率之每種系統,不需要使用不同之 膜材料,及僅需要對於一種半滲透性材料進行生物適合性 (biocompatibility)及毒性試驗。 半滲透性膜塞2 6較佳地係射入模製的3然而,半滲透性 物體可係經甴一種不同之方法而形成膜塞形狀。例如,半 η—---- - 13 - 本紙張尺度適用中國國家標辛(CNS ) Γΰ〇^29Ί^^)---- (請先聞讀背面之注意事項再填窍本頁 ^- 訂 446552 A7 B7 經濟部中央標準局員工消费合作社印黑 五、發明説明(11 ) 滲透性物體吓可係自擠製、射入模製、旋轉模製、熱形 成、壓縮模製、及其他已知之澆注方法而製造。 圖1-3圖不根據本發明之滲透性輸送裝置1〇之兩種實 例。於圖中圖示之結構係滲透性輸送系統之實例及不解釋 爲限制本發明。本發明通常係可應用於具有任何數目之形 狀之所有之滲透性輸送裝置,及可應用於任何種類之方法 諸*4服置於反芻動物之瘤胃内(ruminal)、及可植入之 渗透性輸送技術而苑用於人類或動物中之所有此等裝置。 圖4顯不’與根據本發明之滲透性輸送裝置之釋出速率比 較’具有一種習用之桶而不具有孔之滲透性輸送裝置之有 ϋ劑釋出速率。如於圖4中表示,釋出速率係經由圍繞膠 囊開口端之周圍添加丨〇個圓形孔而以約1與丨〇微升/小時之 間之數量增加s於試驗之輸送裝置中孔3 0之直徑係約1 4百 分比I膜之直徑。於釋出速率中增加之數量部分地係視膜 保持孔之直徑而定。 適合於半參透性膜塞2 6之半滲透性组合物於此技藝中係 已知的’其等之實例係於美國專利第4,874,388號中揭示, 其之整個揭示係以提及之方式併入本文。可自其製造膜塞 2 6 t此等可能之半滲透性材料包括,但不受限於,例如 Hytrel聚醋彈性體(杜邦公司(E)uP〇nt)) '纖維素酯、纖維素 酸、及纖維素酯-醚 '增進水通量(water flux)之乙烯乙酸 乙烯酷共聚物、經由摻和—種剛性聚合物與水溶性低分子 量化合物而製造之半滲透性膜、及於此技藝中熟知之其他 半渗透性材料。以上之纖維質聚合物於脱水葡萄糖 ____一_- 14- 本纸伕尺度適用尹國國家樣毕(CNS ) Λ4規格(2iOx297公释) (請先閱讀背面之注意事項再填荈本頁)
-、1T 線 446552 A7 —_____ B7 五、發明説明(12 ) ~~~~ (anhydroglucose)單位上具有大於夕 六β尺於U主至多至包括3之取代 度,D.S.O”取代度”或..D s 係意表原來存在於包含纖維 素聚合物之脱水葡萄糖單位上、被一種取代基所取代之輕 基之平均數目。代表性之材料包括,但不受限於,選自包 括纖維素醯化產物(acylate)、纖維素二醯化產物、織維素 二醯化產物、乙酸纖維素、二乙酸纖維素、三乙酸纖維 素、單一、二一、及三纖維素烷酸酯、單一、二―、及三 纖維素芳族酸S旨、及其類似物者。典型之纖維素聚合物包 括具有至多1至D.S.及至多21 %之乙醯基含量之乙酸纖維 素.具有1至2之D_S.及21 %至35。/〇之乙醯基含量之乙酸織 維素:具有2至3之D.S_及3 5%至44.80/。之乙醯基含量之乙 酸纖維素、及其類似物。更特定之纖維素聚合物包括具有 1.8至D,S.及39.2%至4 5%之丙醯基含量及2.8至5.4%之羥基 經濟部中央標準局Μ工消贤合作社印- (請先閲靖背面之注意事碩再填窍本頁) 含量之丙酸纖維素:具有1 8之]3 s及丨3 〇/〇至丨5 0/。之乙醢基 含量及3 4 °/。至3 9 °/。之丁酿基含量之纖維素乙酸酯丁酸酯: 具有2。/〇至2 9 %之乙醯基含量、丨7 %至5 3 %之丁醯基含 量、及0.5%至4.7%之羥基含量之纖維素乙酸酯丁酸酯:具 有1.8之D.S.、4 %平均重量百分比之乙醯基含量、及51 % 之丁酷基含量之纖維素乙酸酯丁酸酯:具有2.9至3之D.S. 之纖維素三醯化產物諸如三戊酸纖維素、三月桂酸纖维 素、三软脂酸纖維素 '三琥珀酸纖維素、及三辛酸織维 素;具有2.2至2.6之D.S.之纖維素二酿化產物諸如二破珀 酸纖維素、二軟酯酸纖維素、二辛酸纖维素、二戍酸纖綠 素:纖纖素之共酯(coesters)諸如纖維素乙酸酯丁酸酯及纖 _—___-15- 本紙ft尺度適用中國國家標车(CNS ) A4况格(210X 297公牮) 446552 蛵濟部中央榡準局只工消費合作杜印¾ Λ7 B7 五、發明説明(13 ) 維素、纖維素乙酸酯丙酸酯、及其類似物。 用於膜塞26之其他材料係聚胺甲酸乙酯、聚醚嵌段醯胺 (PEBAX,自億而富阿托肯公司(ELF ATOCHEM, Inc.)市販 的)、及具有某些之親水性之可射入模製之熱塑性聚合物諸 如乙烯一乙烯醇(EVA)。就大體而論,膜塞26係自具有於 1。/。至8 0 % (但較佳地低於5 0 %)之範圍内之水吸收之半滲透 性材料製造。半滲透性膜塞2 6之組合物對於外部液體諸如 水及生物液禮之通過係可渗透的,但對於有益劑、參透性 聚合物(osmopolymers)、渗透劑(osmagents)、及其類似物之通 過,其實質上係不能滲透的。 可使用於膠囊1 2之材料必須係足夠強壯以確保膠囊於植 入之期間遭受之應力下或於因操作之期間產生之壓力而發 生之應力下將不洩漏、破裂、斷裂、或變形。膠囊丨2可係 由於此技藝中已知之化學地惰性並且生物可相容、天然或 合成之材料形成》膠囊材料較佳地係一種非一生物可侵蝕 之材料,其於使用之後留在病患體内,諸如鈦或一種鈦合 金’及對於在膠囊之内及之外之之物質主要地係不能滲透 的。然而’膠囊1 2之材料選擇地可係一種生物可侵蝕之材 料’其於有益劑之分配之後於環境中生物侵蝕。通常,用 於膠囊1 2之較佳材料係對於動物及人體植入物可接受者。 就大體而論’適合於根據本發明之膠囊12之典型之建造 材枓包括非反應性之聚合物或生物可相容之金屬或合金3 聚合物包括丙烯腈聚合物諸如丙烯腈· 丁二烯-笨匕烯三元 聚合物、及其類似物:画化之聚合物諸如聚四氟乙烯、聚 ---------------- - -16 - 本紙張尺^^中關家標準(CNS ) A4祕(2丨GX 297^> (請先聞讀背面之注意事項再填艿本頁)
、1T 涑 4^6552 A7 B7 五、發明説明(14 ) 氯三氟乙烯、四氟乙烯六氟丙烯之共聚物;聚醯亞胺;聚 颯;聚碳酸酯:聚乙烯;聚丙烯;聚氣乙烯·丙烯酸衍生物 共聚物;聚碳酸酯-丙烯腈-丁二烯·苯乙烯;聚苯乙烯;及 其類似物。對於膠囊12有用之金屬材料包括不銹鋼、鈦、 鉑、钽、金、及彼等之合金;以及鍍金之鐵合金、鍍鉑之 鐵合金、路合金及經氛化欽塗佈之不錄鋼。 膠囊12可係自以上揭示之任何之形成壁之材料經由一種 模之使用而生成,視模結構而定,將材料施用於模之上或 於模之内。可使用於製藥工業中已知之任何之寬廣種類之 技術以生成膠囊1 2。 就大體而論,適合於在可移動之分隔構件或活塞22中使 用之材料係彈性體材料,包括以上列出之非反應性之聚合 物'及就大體而論彈性體’諸如聚胺甲酸乙酯及聚醯胺、 氣化橡膠、苯乙烯-丁二烯橡膠 '及氣丁二烯橡膠3 滲透劑係使用以驅動有益劑之流動之—種液體—吸引 劑。滲透劑可係一種osmagent、一種滲透性聚合物 '或兩 者之一種混合物。於osmagent之種類内之物種(即,可溶於 水中並產生驅動水之滲透流入之滲透梯度之非揮發性物種) 經濟部中央標挛局貝工消費合作社印製 --:--:-----士一 —— (請先閱讀背面之注意事項再填窍本頁) 寬廣地變動。實例於此技藝中係熟知的及包括硫酸鎂、氣 化鎂' 硫酸鉀、氣化鈉、硫酸鈉、硫酸鋰、磷酸纳、墙酸 鉀、d-甘露糖醇、葡萄糖醇、肌醇、尿素、琥珀酸鎂、酒 石酸、棉子糖、及多種單醣、寡醣及多醣諸如蔗糖、葡萄 糖、乳糖、果糖、及葡聚糖、以及任何之此等各種物種之 ;’昆合物。 ______ _-17- 本紙伕尺度適用中國國家標準(CNS > A4規格(210X^7公釐)一 --------- 446552 Λ 7 Β7
經濟部中央標準局只Η消费合作社印U 五、發明説明(15 ) 於滲透性聚合物之種類之内之物種係於與水接觸之後潤 脹之親水性聚合物,及此等亦寬廣地變動。滲透性聚合物 可係屬於植物或動物來源、或合成的,及滲透性聚合物之 實例於此技藝中係熟知的。實例包括:具有30,000至 5,000,000之分子量之聚(甲基丙烯酸羥基烷基酯)、具有 10,000至360,000之分子量之聚(乙烯基吡咯啶酮)、陰離子 或陽離子水凝膠、高分子電解質錯合物 '具有低乙酸酯殘 餘物 '視需要與乙二醛、甲醛、或戊二醛交聯並具有2〇〇至 30,000之聚合度之聚(乙烯醇)、曱纖維素、經交聯之瓊脂 與羧甲纖維素之一種混合物、羥丙基曱基纖维素與羧曱纖 維素鈉之一種混合物、N -乙烯基内醯胺之聚合物、聚氧乙 烯-聚氧丙烯凝膠、聚氧丁烯-聚乙烯嵌段共聚物凝膠、槐 樹豆膠、聚丙烯酸衍生物凝膠、聚酯凝膠、聚脲凝膠 (polyuria gels)、聚醚凝膠、聚醢胺凝膠、多肽凝膠、聚胺 基酸凝膠、聚纖維素凝膠、具有250,〇〇〇至4,000,000之分子 量之5¾複乙晞酸性敌基聚合物、Cyanamer聚丙缔酷胺、經 交聯之茚一頌丁烯二酐聚合物、具有80 000至2〇〇 〇〇〇之分 子量之Good-Rite聚丙烯酸、具有i〇〇,〇〇〇至5,〇〇〇,〇〇〇之分子 量之Polyox聚氧化乙烯聚合物、澱粉接技共聚物、及Aqua· Keeps丙晞酸酯聚合物多醣。 滲透劑可係一種固體滲透片劑或一種流體滲透劑。滲透 片劑可係於多種不同之可想像之形狀、組織、密度、及裯 度生成及仍然係於本發明之範圍之内。滲透劑可係經由多 種之技術而製造,其等之多種於此技藝中係知曉的。於一 _______^18- 一 本紙張尺度適用中國國家標羋(CNS ) A4規格(210χ 297公势) (請先閱讀背面之注意事項再填巧本頁} .装. -丁 •-° .涑 i 446552 經濟部中央標準局ΜΧ消於合作社印¾ 五、發明説明(16 ) 種此等技術中’滲透活性之劑係如固體或半固體配製物製 備及壓製成爲顆粒或片劑’其之尺寸對應於略微小於在聲 囊内部其將佔據之分別之室之内部尺寸。視使用之材料之 本質而定,可包括之劑及其他固體成分可係於顆粒之生成 之則經由程序諸如球研磨、壓延、攪拌、或輥研磨而處 理,以達成微細之粒子尺寸及因此每種成分之相當一致之 混合物。 於裝配根據本發明之一種較佳具體實施例之滲透性輸送 裝置10中’膠囊12係經由圍繞膠囊之開口端14形成多個 之孔3 0而製備。孔3 〇可係經由機械瓒孔、雷射鑽孔、模 製、或任何其他已知方法而生成。—旦已製備具有多個之 孔30(其具有達成有益劑之需要之輸送速率之數目及尺寸) 之後’將活塞22插入膠囊12之中。一旦已形成滲透劑顆粒 或片劑之後’將彼等置於預形成膠囊之内於第二室2〇之内 於活塞2 2之頂部上。然後將膜塞2 6,根據本發明之一項具 體實施例’置入膠囊丨2之開口端丨4之中以關閉並密封滲透 性輸送系統之一末端。 輸送口 1 6係經由於此技藝中知曉之習用技術而生成之一 種孔口。包括於此等方法中者係機械鑽孔、雷射鑽孔、及 模製。膠囊12包含至少一個此種輸送口 16,及於大多數構 造中’一個輸送口將係足夠的。然而,可存在兩個或兩個 以上輸送口 16而不違背本發明。以直徑及長度表示之口 16 之尺寸將隨著有益劑之類型、輸送有益劑之速率、及輸送 其進入之環境而變動。對於任何特定之膠囊丨2或有益劑決 ----------- - 19 - 本錄尺度侧+朗家縣(⑽)44驗(210X297公炸) (請先閱讀背面之注意事項再填荇本頁) - 訂 壤 446552 A 7 B7 經濟部中央橾孪局®;:工消费合作社印m 五 '發明説明(17 定輸送口之最適尺寸及適合之尺寸之選擇中包括之考慮因 素’對於熟請此技藝者將係容易地明白的。 根據本發明之一項具體實施例,於膠囊12之第—室18中 i。之有益劑係一種可成動之組合物諸如一種流體、懸浮 夜、或漿液,及通常係於已插入滲透劑及活塞22之後倒入 膠囊t第一室18中3然而,第—室18亦可係於活塞之插入 之前通過開口端而塡充。 说大體而論,本發明應用於有益劑之施用,其包括任何 生理上或藥理學上活性之物質。可經由本發明而輸送之藥 劑包括對於周圍神經 '腎上腺素受體、膽鹼受體、骨絡 肌、心血管系統、平滑肌、血液循環系統、syn〇ptic shes、 神經效應器接合位置、内分泌與激素系統、免疫系統、生 殖系統、骨骼系統、内泌素系統'消化與排洩系統、组織 胺系統及中樞神經系統作用之藥物。適合之劑可係選自, 例如,蛋白質、酵素'激素、核酸、核蛋白、多醣、醣蛋 白、脂蛋白、多肽'類固醇、止痛劑、局部麻醉劑、抗生 素劑、消炎皮質類固醇、眼藥及此等物種之合成類似物。 可係經由本發明之裝置而輸送之藥物之實例包括,但不 受限於,甲哌氣丙呼乙二磺酸鹽、硫酸亞鐵、胺基己酸、 梅坎米胺氫氣酸鹽、普魯卡因醯胺氫氣酸鹽、安非他命较 酸鹽 '税氧麻黃驗氫氣酸鹽、benzamphetamine hydrochloride、異丙腎上腺素硫酸鹽、苯甲嗎啉氫氣酸 鹽、虱化甲氨酷甲基膽絵·'氣化乙酷甲膽驗、毛果芸给氡 氣酸鹽、阿托品硫酸鹽、溴化莨菪礆、碘化異丙醯胺、 20- 衣紙張尺度適用中國國家標率(CNS ) A4規格(210X297公犛 (讳先閱禎背面之注意事項再填符本頁) ^, "β 446552 經濟部中央標準局負Η消费合作社印製 A 7 B7 五、發明説明(18 ) 化環己基經苯丙基三乙胺、苯乙雙脈氫氡酸鹽、苯喊啶醋 酸甲醋氩氣酸鹽、茶檢胆驗鹽(theophylline cholinate)、去 氧頭孢菌烷酸氫氣酸鹽、二苯哌啶丁醇、美基敏氫氣酸 鹽、曱哌氣丙啼順丁烯二酸、苯氧基/?-優卡因、乙硫匹拉 畊順丁烯二酸鹽、茴茚酮(amsindone)、二苯乙醯茚滿二酮 赤蘇醇基四硝酸酯、長葉毛地黃苷、氟磷酸異丙酯、乙醯 偶氮胺、甲酷唆胺、字氟I»塞嗔、chloropromaide、曱確氮苯 脲、氣地孕酮醋酸酯、氣苯甲基丁烷二醇、別嘌呤醇、乙 醯柳酸鋁、胺基曱葉酸、乙醯基磺胺異,号唑、紅黴素、氫 基可體松、氫基皮質脂酮醋酸酯、皮質酮醋酸酯、地塞米 松及其之衍生物諸如倍地米松、氟羥潑尼松龍、甲基睪固 醇、17-S -動情二醇、乙块基動情二醇、乙炔基動情二醇 3 -甲基謎 '去氩皮質脂醇、17 -々-經孕嗣醋酸醋、19 -去 甲孕_ 、乙烯異结酮、块諾網、避孕固酮、 norethiederone、黃禮激素、三烯決諾酮、經块諾嗣、阿司 匹靈、消炎痛、甲氧莕丙酸、苯氧基氫化阿托酸、蘇靈 大、茚酮苯丙酸 '硝化甘油、異山梨糖醇二硝酸酯、必得 安' If塞嗎心安、1驢心安、心得舒、甲膀味狐、氣壓定、 丙咪-并、左旋多巴、氣丙畊、甲基多巴、二羥基苯基丙胺 酸、茶给、葡萄糖酸ί弓、嗣基布洛芬、異丁笨丙酸、去氧 頭孢菌烷酸、紅黴素、氟哌啶醇、氣茶醯二甲基吡咯乙 酸、乳酸亞鐵、長春胺、氣甲笨基苯幷二氮萆酮、苯氧基 苯甲胺、硫氮革酮、甲腈吹酮、Capr〇pril、mand〇1、 quanbenz、二氫氣嘍、糖硝烯二胺 '氟聯苯丙酸、 _______-21 - 本纸ft尺度通用中國國家標準(CMS } A4说格(210X297公;------ (請先閔讀背面之注意事項再填艿本頁) - 丁 •-'° 446552 經濟部中央標準局只工消费合作社印製 Λ7 B7 五、發明説明(19 ) fenufen、2-(3 -氟基-4-聯苯基)丙酸(fluprofen)、四苯酷17比 嘻乙酸、烯氣苯乙酸、曱滅酸、氟滅酸' difuinal、 nimodipine、硝吡乙甲酯、硝吡丁甲酯、硝吡胺曱酯、 felodipine、利多氟 秦' 口塞燒丙胺、gallopamil、 amlodipine、mioflazine、lisinolpril、乙氧苯丙 Μ 酸、 enalaprilat '疏基甲基氧丙基天旋捕胺酸、ramipril、法莫 替丁、nizatidine、胃潰寧、etintidine、tetratolol、長壓· 定、曱氨二氮萆 '氣甲苯基苯幷二氮萆酮、阿密西替林' 及丙咪畊。另外之實例係蛋白質及肽,其等包括,但不受 限於’胰島素、秋水仙铪' 胰高血糖激素、促甲狀腺激 素、甲狀旁腺與垂體激素、降血句素、腎激素、催乳激 素、促腎上腺皮質激素、促甲狀腺激素、促卵泡激素、脈 絡獏親生殖腺素、性腺激素釋出因子、牛生長激素、豬生 長激素、催產激素、後葉加壓素、促性腺激素釋出因子、 崔乳激素、生長激素釋放抑制因子、賴胺酸加壓素、腸促 姨酶素、促黃體激素、促黃體激素釋出因子 '促黃體激素 釋出因子顯效藥與拮抗藥、輔氨醯氨酸、干擾素、白細胞 介素、生長激素諸如人體生長激素、牛生長激素與豬生長 激素、致育抑制劑諸如前列腺素、致育促進劑、生長因 子、血液凝固因子、人類胰臟激素釋放因子、此等化合物 之類似物與衍生物、及此等化合物之製藥上可接受之碧、 或彼等之類似物或衍生物。 於分子之層次上,有益劑之各種形式可包括未帶電荷之 分子、分子錯合物、及製藥上可接受之酸加成鹽或鹼加成 {請先閱讀背面之注意事項再填巧本I)
11T 446552 Λ 7 Β7 五、發明説明(20 ) —~一" "" '~ 鹽諸如氫氣酸鹽、氩溴酸鹽、醋酸鹽、硫酸鹽、月桂酸 鹽' 油酸鹽、及柳酸鹽。對於酸性化合物,可使用金屬之 鹽、胺或有機陽離子。亦可使用衍生物諸如酯、醚及醯 胺。可單獨地使用一種有益劑或其可與其他劑混合。該有 垃劑可視需要包括製藥上可接受之載體及/或另外之成分諸 如抗氧化劑、安定劑、滲透増進劑、及其他。 根據本發明之其他具體實施例’囊12可採用不同之形 式。例如,輸送孔口 16可係於插入膠囊12中之一種軟性不 能渗透之材料輸送塞中形成。此外,可移動之分隔構件或 活塞2 2可係一種撓性之構件諸如一種隔膜、隔板、餐 '平 板 '球體、或剛性之金屬合金,及可係由任何數目之惰性 材料製造。此外,於滲透劑與有益劑之問簡單地具有一種 界面,不具有活塞22之滲透性裝置可發生作用。 經濟部中央標準局只工消费合作社印裂 (請先閲請背面之注意事項再填κ:本頁} 使用本發明之系統而可施用有益劑之動物包括人類及其 他動物。本發明對於應用於人類及家庭飼養動物、競赛用 動物、及農場飼養動物,特定言之對於哺乳動物,係持別 有關的。對於有益劑之施用於動物,本發明之裝置可係皮 下地或腹膜内地植入,其中水性體液係有效以活化.采透 劑。本發明之裝置亦可施用於反芻動物之瘤胃,其中具^ 實施例裝置可進一步包含一種密度元件以維持裝置於瘤胃 中歷時至多120天或較長之延長之時間期間。密度元件_於藥^ 物輸送裝置之技藝中係熟知的。 本發明之輸送裝置於生理或水性環境以外之環境中亦係 有用的。例如,輸送裝置可係使用於靜脈系統中(例如,連 ____-23-___ 本紙張尺度適用中國國家標準(CN'S ) A4規格(210X297公釐) ~ ~ 446552 A7 ____ B7 1" "" 五、發明説明(2*i ) 接於一種靜脈注射系或袋或一種靜脈注射瓶)以輸送有益劑 至—種物,主要至人體。彼等亦可係使用於人工肺(blood oxygenators)、腎透析及電泳中°此外,本發明之輸送裝置 可使用於生物技術領域中,諸如輸送營養物或生長調節之 化合物至細胞培養》於此等案例中,活化機構諸如機械機 構係特別有用的°有益劑可係對於輸送至人類或動物之身 體中已知之任何之劑諸如藥物' 維生素、營養物、或其類 似物。有益劑亦可係輸送至其他類型之水性環境諸如池 淹、水槽、蓄水池、及其類似物之劑。於此種類型之劑中 包括符合此種欽述者係農藥;消毒劑 '營養劑、維生素、 食品補充劑、化學不孕劑(sex sterilants)、生育抑制劑及生 育促進劑。 雖然已參考本發明之較佳具體實施例詳細地説明本發 明’但是可作各種改變、及使用相等之事物而不達背本發 明,此對於熟諳此技藝之人士將係明白的。 (請先閱讀背面之注意事項再填艿本頁) ^1 線 經濟部中央標準局負工消费合作社印-
Claims (1)
- 經濟部申央標孪局員工消費合作社印製 Α8 Β8 CS D8 六、申請專利範圍 1. 一種滲透性輸送裝置,包含·- 具有一種實質上圊筒形側壁、具有一種有益劑輪送孔 口之第一末端、及第二開口端之一種輸送裝置膠囊; 安置於輸送裝置膠囊之内及於輸送膠囊之内於縱向中 可移動以分配有益劑之一種分隔構件; 於鄰接分隔構件之一側安置之一種參透性器具; 於鄰接輸送裝置膠囊之第二開口端之實質上圓茼形側 壁中之多個之開口; 安置於輸送裝置膠囊之第二開口端之内及覆蓋於實質 上圓筒形側壁中之每個之多個開口並經由多個之開口而 保持於膠囊中之一種膜塞。 2. 如申請專利範圍第1項之滲透性輸送裝置,其中該膜塞 係由一種材料形成,此種材料潤脹造成一部分之膜塞延 伸進入於側壁中之開口中’增加於膜塞與輸送裝置膠囊 之間之摩擦及防止膜塞自輸送裝置膠囊排出。 3. 如申請專利範圍第1項之滲透性輸送裝置,其中於側壁 中之該開口係容許流體通過開口進入膜塞中及進入於輸 送裝置膠囊内之滲透性器具中之通孔。 4. 如申請專利範圍第1項之滲透性輸送裝置,其中該間口 係以一種環狀方式圍繞該側壁間隔之圓筒形孔β 5. 如申請專利範園第1項之滲透性輸送裝置,其中該實質 上圓筒形倒壁於該輸送裝置殼之開口端包括一種向内方 向之環狀唇,其提供該膜於該輸送裝置殼之第二開口端 中之另外之保持。 __ -25- 本紙伕足度適用中國國家ϋ ( CNS Μ4说格(210X29*7公釐) {讀先閱讀背面之注意事項再填寫本f ) '1T it 經濟部中央標準局員工消费合作社印51 446552 A8 B8 C8 D8 六、申請專利範圍 6. —種滲透性輸送裝置,包含: 一種輸送裝置本體,其包含將通過輸送裝置本體之一 種輸送孔口而輸送之一種有益劑、及用於吸收外部液體 進入輸送裝置本體以致使有益劑受輸送之一種滲透劑; 及 固牢於輸送裝置本體之開口端中及容許外部液體通過 其進入輸送裝置本體之一種膜塞,該膜塞係經由於輸送 裝置本體中圍繞輸送裝置本體之開口端形成之多個孔而 固牢於輸送裝置本體之開口端,該膜塞係可膨脹的以廷 伸進入多個之孔中以防止該膜塞自輸送裝置本體之排 出。 7. 如申請專利範園第6項之滲透性輸送裝置,其中該輸送 裝置本體另外包含分隔包含該有益劑之第一貯器與包含 該滲透劑之第二貯器及當該滲透劑通過該膜而吸收外部 液體時致使該有.益劑係通過該輸送孔口而輸送之一種可 移動之活塞。 8. 如申請專利範圍第6項之滲透性輸送裝置,其中外部液 體係通過膜經由該輸送裝置本體之開口端及該多個之孔 而吸收進入該輸送裝置本體中。 9. 如申請專利範圍第6項之滲透性輸送裝置,其中該多伺 之孔係以一種環狀方式圍繞該輸送裝置本體之一側壁弇 接該輸送裝置本體之開口端間隔之圓筒形孔。 10. 如申請專利範圍第6項之滲透性輸送裝置,其中該輸送 裝置本體具有一種實質上圓筒形側壁及該多個之孔係於 -26- 本纸張尺度適用中國國家標準(CNS ) Λ4規格(2!0x :^7公鏠: (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部中央標^局負工沾费合作社'^^^ 4^6552 A8 BS C8 __ DS * -------------- 六、申請專利範圍 該實質上圓筒形側壁中形成。 11‘如申請專利範圍第10項之滲透性輸送裝置,其中該實質 上圓筒形側壁於該輸送装置本體之開口端包括—種向内 方向之環狀唇,其提供該膜於該輸送裝置本體中之另外 之保持。 12_ —種具有一可控制之有益劑輸送速率之可植入之渗透性 有益劑輸送装置,包含: 具有一種有益劑輸送孔口及一種開口端之一種實質上 圓筒形本體; 於該實質上圓筒形本體之一側壁中於該開口端形成之 多個之開口,多個之開口係屬於爲了達成一種預定之有 益劑輸送速率所決定之尺寸及數目;及 容納於該本體之開口端中並覆蓋該多個之開口之一種 膜塞。 13. 如申請專利範圍第1 2項之可植入之滲透性有益劑輸送裝 置,其中該膜塞潤脹進入該多個之開口中以防止該膜塞 之排出。 14. 如申請專利範圍第1 2項之可植入之滲透性有益劑輸送裝 置,其中該多個之開口容許流體通過該側壁及通過該膜 塞而進入該本體之内部中。 15. —種保持一種膜塞於一種可植入之淨透性裝置中之方 法,包含: 形成一種實質上圓柱形之膜塞; 於一種膠囊之側壁中鄰接膠囊之一開口端形成孔: -27- 本纸张尺度逍用中國国家標準(CNS ) Λ4洗格(210乂;!97公笼· "" ' 一 (請先閔讀背面之注意事項再填寫本頁) -i_ 4 46 55 2 A8 B8 C8 D8 六、申請專利範圍 將實質上圓柱形之膜塞插入膠囊之開口端中致使膜塞 覆蓋於側壁中形成之孔;及 致使膜塞潤脹進入於側壁中之孔中以保持膜塞於膠囊 中。 16.如申請專利範圍第1 5項之保持一種膜塞於一種可植入之 滲透性裝置中之方法,其中水通過該膜通過該膠囊之開 口端及通過該孔而進入該膠囊中。 (請先聞讀背面之注意事項再填寫本頁) ^ Γ 經濟部中央標绛局員工消費合作社印衮 本紙张尺度通用中國國家標準(CNS ) Λ4说格(2ΙΟΧ π7公趁
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6898797P | 1997-12-29 | 1997-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW446552B true TW446552B (en) | 2001-07-21 |
Family
ID=22085978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW087121719A TW446552B (en) | 1997-12-29 | 1998-12-28 | Osmotic delivery system with membrane plug retention mechanism |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US6270787B1 (zh) |
| EP (1) | EP1041968B1 (zh) |
| JP (1) | JP4173635B2 (zh) |
| AR (1) | AR014194A1 (zh) |
| AT (1) | ATE260640T1 (zh) |
| AU (1) | AU1828599A (zh) |
| CA (1) | CA2316976C (zh) |
| DE (1) | DE69822208T2 (zh) |
| ES (1) | ES2217613T3 (zh) |
| TW (1) | TW446552B (zh) |
| WO (1) | WO1999033446A1 (zh) |
| ZA (1) | ZA9811880B (zh) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
| WO1999033446A1 (en) * | 1997-12-29 | 1999-07-08 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| CA2356860C (en) * | 1998-12-31 | 2006-11-07 | Alza Corporation | Osmotic delivery system having space efficient piston |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| EP1328256B1 (en) * | 1999-12-21 | 2005-10-19 | Alza Corporation | Valve for osmotic devices |
| US7163688B2 (en) * | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
| US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1494998A2 (en) * | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| EP1536767B1 (en) * | 2002-06-17 | 2007-08-08 | Alza Corporation | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
| MXPA05000232A (es) * | 2002-06-21 | 2005-06-17 | Transform Pharmaceuticals Inc | Composiciones farmaceuticas con disolucion mejorada. |
| CN100453130C (zh) | 2002-06-26 | 2009-01-21 | 精达制药公司 | 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞 |
| US7014636B2 (en) * | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
| RU2342118C2 (ru) * | 2002-12-19 | 2008-12-27 | Алза Корпорейшн | Стабильные неводные однофазные гели и композиции на их основе для доставки из имплантируемого устройства |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| EP2339328A3 (en) | 2002-12-30 | 2011-07-13 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of celecoxib |
| AU2003272270A1 (en) | 2003-02-28 | 2004-09-28 | The Regents Of The University Of Michigan | Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1613389B8 (en) | 2003-03-31 | 2008-05-07 | Intarcia Therapeutics, Inc. | Osmotic pump with means for dissipating internal pressure |
| CA2520766A1 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
| US20050008661A1 (en) | 2003-03-31 | 2005-01-13 | Fereira Pamela J. | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| US20040214893A1 (en) * | 2003-04-11 | 2004-10-28 | Matthew Peterson | Gabapentin compositions |
| EP1626950A4 (en) | 2003-05-23 | 2007-05-23 | Transform Pharmaceuticals Inc | SERTRALINZUSAMMENSETZUNGEN |
| NZ586198A (en) * | 2003-09-26 | 2011-12-22 | Alza Corp | Oros push-stick sustained release dosage forms for controlled delivery of active agents |
| EP2184058B1 (en) | 2003-09-26 | 2012-02-08 | ALZA Corporation | Drug coating providing high drug loading and methods for providing the same |
| US20070259033A1 (en) | 2003-09-26 | 2007-11-08 | Evangeline Cruz | Controlled release formulations exhibiting an ascending rate of release |
| US20050158382A1 (en) * | 2003-09-26 | 2005-07-21 | Evangeline Cruz | Controlled release formulations of opioid and nonopioid analgesics |
| BRPI0414941A (pt) | 2003-09-30 | 2006-11-07 | Alza Corp | dispositivo de distribuição de agente ativo acionado osmoticamente proporcionando um perfil de liberação ascendente |
| PL380763A1 (pl) * | 2003-10-31 | 2007-03-05 | Alza Corporation | Pompa osmotyczna z samoczynnie mocowanym korkiem membranowym szybkiego uruchamiania |
| US20050113410A1 (en) * | 2003-11-03 | 2005-05-26 | Mark Tawa | Pharmaceutical salts of zafirlukast |
| KR20060121890A (ko) * | 2003-11-06 | 2006-11-29 | 알자 코포레이션 | 이식형 삼투 펌프와 함께 사용하기 위한 모듈식 흡수율감소기 |
| CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2005092065A2 (en) * | 2004-03-25 | 2005-10-06 | Transform Pharmaceuticals, Inc. | Novel tricyclic compounds and related methods of treatment |
| US20080022287A1 (en) * | 2004-03-31 | 2008-01-24 | Koninklijke Philips Electronics, N.V. | Method And System For Transferring Budgets In A Technique For Restrained Budget Use |
| US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
| US7803786B2 (en) * | 2004-06-17 | 2010-09-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
| JP2008510558A (ja) | 2004-08-27 | 2008-04-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 少なくとも1つの薬剤を投与する、電子制御され、遠隔制御されるピル及びシステム |
| US8541026B2 (en) * | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
| WO2006073779A1 (en) * | 2004-12-30 | 2006-07-13 | Transform Phamaceuticals, Inc. | Novel omeprazole forms and related methods |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| EP1877077A2 (en) * | 2005-02-03 | 2008-01-16 | Intarcia Therapeutics, Inc. | An implantable interferon-containing device |
| US7959938B2 (en) * | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
| EP1906867A1 (en) * | 2005-06-30 | 2008-04-09 | Alza Corporation | Osmotic intraosseous drug delivery system |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US7931620B2 (en) * | 2006-02-01 | 2011-04-26 | Roche Diagnostics International Ag | Self-sealing connection for housing shells of an administering device |
| EP2015805A1 (en) * | 2006-04-28 | 2009-01-21 | Koninklijke Philips Electronics N.V. | Osmotic pump with at least one chargeable material |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| MX2009001114A (es) | 2006-08-09 | 2009-02-10 | Intarcia Therapeutics Inc | Sistemas de suministro osmotico y ensambles de piston. |
| US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
| US8617143B2 (en) * | 2006-12-07 | 2013-12-31 | The Regents Of The University Of California | Therapeutic agent delivery systems and devices |
| EP2786985B1 (en) | 2007-02-09 | 2018-11-28 | Metabasis Therapeutics, Inc. | Antagonists of the glucagon receptor |
| CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| EP2192892A2 (en) * | 2007-07-27 | 2010-06-09 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
| MX2010001784A (es) | 2007-08-13 | 2010-03-15 | Metabasis Therapeutics Inc | Activadores novedosos de la glucocinasa. |
| JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN104803891B (zh) | 2008-08-13 | 2017-10-20 | 症变治疗公司 | 胰高血糖素拮抗剂 |
| US20100092566A1 (en) * | 2008-10-15 | 2010-04-15 | Alessi Thomas R | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| JP5681875B2 (ja) | 2009-04-07 | 2015-03-11 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | モジュラ経口摂取医薬品供給カプセル |
| WO2011018753A1 (en) * | 2009-08-12 | 2011-02-17 | Koninklijke Philips Electronics N.V. | Drug delivery device with compressible drug reservoir |
| DK2462246T3 (da) | 2009-09-28 | 2017-11-06 | Intarcia Therapeutics Inc | Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse |
| US8969327B2 (en) | 2010-04-08 | 2015-03-03 | Emory University | Substituted androst-4-ene diones |
| AU2011296258B2 (en) | 2010-08-30 | 2015-07-09 | SinuSys Corporation | Devices for dilating a paranasal sinus opening and for treating sinusitis |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9585930B2 (en) | 2011-03-20 | 2017-03-07 | Trustees Of Boston University | Therapeutic agent for emphysema and COPD |
| CN103781474B (zh) * | 2011-03-24 | 2018-09-21 | 宝珍那提公司 | 可吞咽的药物胶囊 |
| ITFI20110114A1 (it) | 2011-05-31 | 2012-12-01 | Scuola Superiore Di Studi Universit Arie Di Perfe | Piattaforma robotica per chirurgia mininvasiva |
| WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
| US20130090633A1 (en) * | 2011-10-07 | 2013-04-11 | University Of Southern California | Osmotic patch pump |
| TWI615155B (zh) * | 2011-11-01 | 2018-02-21 | 拜耳股份有限公司 | 滲透活性的陰道遞送系統 |
| JP2015509786A (ja) | 2012-02-29 | 2015-04-02 | サイナシス コーポレーション | 副鼻腔開口部を拡張して副鼻腔炎を治療するためのデバイスおよび方法 |
| US9737364B2 (en) | 2012-05-14 | 2017-08-22 | Vanderbilt University | Local magnetic actuation of surgical devices |
| JP6235001B2 (ja) | 2012-05-21 | 2017-11-22 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ベンゾチエノピリミジン |
| US9826904B2 (en) | 2012-09-14 | 2017-11-28 | Vanderbilt University | System and method for detecting tissue surface properties |
| US20140081169A1 (en) * | 2012-09-17 | 2014-03-20 | Vanderbilt University | System and method of tetherless insufflation in colon capsule endoscopy |
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| CN102871982B (zh) | 2012-10-16 | 2014-09-10 | 中国科学院上海药物研究所 | 一种药物渗透泵制剂 |
| WO2014113697A1 (en) | 2013-01-17 | 2014-07-24 | Vanderbilt University | Real-time pose and magnetic force detection for wireless magnetic capsule |
| US9687263B2 (en) | 2013-05-30 | 2017-06-27 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
| CA2924141C (en) | 2013-08-22 | 2022-06-07 | The General Hospital Corporation | 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase |
| WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| CN107205623A (zh) | 2014-09-09 | 2017-09-26 | 范德比尔特大学 | 用于低资源地区中的胃癌筛查的喷液式胶囊内窥镜和方法 |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| AU2016349381B2 (en) | 2015-11-05 | 2023-02-23 | The General Hospital Corporation | Intrathecal delivery of nucleic acid sequences encoding ABCD1 for treatment of adrenomyeloneuropathy |
| MA53353A (fr) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| SG11201903462UA (en) | 2016-10-20 | 2019-05-30 | Peptron Inc | Methods of delivering a neuroprotective polypeptide to the central nervous system |
| KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
| US20200188479A1 (en) | 2017-03-08 | 2020-06-18 | Intarcia Therapeutics, Inc. | Apparatus and methods for administration of a nauseogenic compound from a drug delivery device |
| US11122965B2 (en) | 2017-10-09 | 2021-09-21 | Vanderbilt University | Robotic capsule system with magnetic actuation and localization |
| EP3752249A1 (en) | 2018-02-13 | 2020-12-23 | Ligand Pharmaceuticals, Inc. | Glucagon receptor antagonists |
| USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
| BR112021006823A2 (pt) | 2018-10-11 | 2021-07-27 | Intarcia Therapeutics, Inc. | polipeptídeos análogos de amilina humana e métodos de uso |
| US20200155466A1 (en) * | 2018-11-21 | 2020-05-21 | II Don S. Houtz | Oral Medicine Delivery Capsule |
| CN109589491B (zh) * | 2019-01-29 | 2024-01-09 | 上海安翰医疗技术有限公司 | 自动给药装置 |
| KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
| KR20230145053A (ko) | 2021-01-12 | 2023-10-17 | 듀렉트 코퍼레이션 | 지속 방출 약물 전달 시스템 및 관련 방법 |
| WO2025160155A1 (en) | 2024-01-22 | 2025-07-31 | The Broad Institute, Inc. | Epigenetic targeting of prion diseases |
| WO2025194118A1 (en) | 2024-03-15 | 2025-09-18 | Children's Hospital Medical Center | Formulations and methods for alleviating sleep disorders |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3732865A (en) | 1971-01-13 | 1973-05-15 | Alza Corp | Osmotic dispenser |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3929132A (en) * | 1973-04-10 | 1975-12-30 | Alza Corp | Osmotic dispenser |
| US3995632A (en) | 1973-05-04 | 1976-12-07 | Alza Corporation | Osmotic dispenser |
| US3916889A (en) | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
| US3888249A (en) * | 1973-11-02 | 1975-06-10 | David L Spencer | Arterial infusion catheter |
| US4111203A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US4203439A (en) | 1976-11-22 | 1980-05-20 | Alza Corporation | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom |
| US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4243030A (en) | 1978-08-18 | 1981-01-06 | Massachusetts Institute Of Technology | Implantable programmed microinfusion apparatus |
| US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
| US4340054A (en) | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4552561A (en) | 1982-12-23 | 1985-11-12 | Alza Corporation | Body mounted pump housing and pump assembly employing the same |
| US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
| US4865845A (en) | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
| US4874388A (en) | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
| US5151093A (en) | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
| GB9027422D0 (en) | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
| US5137727A (en) | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
| US5223265A (en) | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
| US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
| US5456679A (en) | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
| US5980508A (en) * | 1994-06-22 | 1999-11-09 | Controlled Release Technologies Pty Ltd | Controlled release device and method |
| US5731001A (en) * | 1995-06-07 | 1998-03-24 | Magruder; Judy A. | Locking couplings for osmotic delivery devices |
| PL189289B1 (pl) * | 1996-02-02 | 2005-07-29 | Alza Corp | Sposób przygotowania implantowanego układu do dostarczania substancji aktywnej |
| WO1999033446A1 (en) * | 1997-12-29 | 1999-07-08 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| KR100568917B1 (ko) * | 1997-12-30 | 2006-04-07 | 알자 코포레이션 | 멤브레인 플러그를 갖는 익제 전달장치 |
-
1998
- 1998-12-15 WO PCT/US1998/026654 patent/WO1999033446A1/en not_active Ceased
- 1998-12-15 CA CA002316976A patent/CA2316976C/en not_active Expired - Fee Related
- 1998-12-15 DE DE69822208T patent/DE69822208T2/de not_active Expired - Lifetime
- 1998-12-15 AU AU18285/99A patent/AU1828599A/en not_active Abandoned
- 1998-12-15 AT AT98963215T patent/ATE260640T1/de not_active IP Right Cessation
- 1998-12-15 EP EP98963215A patent/EP1041968B1/en not_active Expired - Lifetime
- 1998-12-15 JP JP2000526203A patent/JP4173635B2/ja not_active Expired - Fee Related
- 1998-12-15 ES ES98963215T patent/ES2217613T3/es not_active Expired - Lifetime
- 1998-12-22 US US09/217,823 patent/US6270787B1/en not_active Expired - Lifetime
- 1998-12-28 AR ARP980106698A patent/AR014194A1/es active IP Right Grant
- 1998-12-28 ZA ZA9811880A patent/ZA9811880B/xx unknown
- 1998-12-28 TW TW087121719A patent/TW446552B/zh not_active IP Right Cessation
-
2001
- 2001-05-17 US US09/858,631 patent/US6976981B2/en not_active Expired - Lifetime
- 2001-05-17 US US09/858,632 patent/US6899887B2/en not_active Expired - Lifetime
-
2004
- 2004-07-07 US US10/885,828 patent/US20040243106A1/en not_active Abandoned
- 2004-10-08 US US10/962,130 patent/US20050048097A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2316976C (en) | 2009-02-17 |
| US20010021822A1 (en) | 2001-09-13 |
| JP4173635B2 (ja) | 2008-10-29 |
| EP1041968B1 (en) | 2004-03-03 |
| ES2217613T3 (es) | 2004-11-01 |
| WO1999033446A1 (en) | 1999-07-08 |
| US6270787B1 (en) | 2001-08-07 |
| ATE260640T1 (de) | 2004-03-15 |
| US20010022974A1 (en) | 2001-09-20 |
| DE69822208T2 (de) | 2005-04-28 |
| EP1041968A1 (en) | 2000-10-11 |
| ZA9811880B (en) | 1999-06-29 |
| HK1031332A1 (zh) | 2001-06-15 |
| DE69822208D1 (de) | 2004-04-08 |
| US20040243106A1 (en) | 2004-12-02 |
| US6899887B2 (en) | 2005-05-31 |
| US20050048097A1 (en) | 2005-03-03 |
| CA2316976A1 (en) | 1999-07-08 |
| US6976981B2 (en) | 2005-12-20 |
| AR014194A1 (es) | 2001-02-07 |
| JP2001526939A (ja) | 2001-12-25 |
| AU1828599A (en) | 1999-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW446552B (en) | Osmotic delivery system with membrane plug retention mechanism | |
| JP4494629B2 (ja) | メンブレンプラグを備えた有益な作用剤の供給システム | |
| KR101046903B1 (ko) | 삼투성 약물 전달 시스템을 위한, 최소로 튀는 용적효율성 피스톤 | |
| CN100548411C (zh) | 设置有内部压力释放部件的渗透泵 | |
| US5318558A (en) | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect | |
| KR100734187B1 (ko) | 삼투성 장치용 밸브 | |
| ES2226159T3 (es) | Aparato modulador de caudal para sistema de liberacion osmotica. | |
| CN1139411C (zh) | 具有可自调节出口的可植入释放装置 | |
| JP4383674B2 (ja) | 空間効率のよいピストンを有する浸透圧送達システム | |
| JP2001510791A (ja) | 半透性プラグを備えた浸透投与系 | |
| JPH07500264A (ja) | 疎水性壁材料による浸透圧薬物投与デバイス | |
| JP2007509703A (ja) | 自己保持性、迅速スタート膜プラグを有する浸透式ポンプ | |
| ES2203824T3 (es) | Sistema de administracion osmotica y procedimiento para mejorar su arranque y funcionamiento. | |
| US5227167A (en) | Long-term delivery device including hydrophobic loading dose | |
| KR100428273B1 (ko) | 약물전달의지연된활성화및완전한약물방출기능을갖는삼투장치 | |
| HK1031332B (zh) | 备有膜塞子保留机理的渗透性传送系统 | |
| MXPA99008737A (en) | Implantable delivery device with self adjustable exit port |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |